Integral Health Asset Management, LLC
Long book
$1.89B
Q1 2026
Positions
86
Top-10 weight
47%
concentration
Last quarter
+19.8%
SPY +14.8%
Turnover
48%
of book per quarter
Strategy in plain words
auto-generated from filingsIntegral Health Asset Management, LLC is a diversified fundamental manager, specialised in healthcare (91% of the long book), running a $1.89B US long book across 86 positions.
The portfolio is moderately concentrated (top 10 ≈ 47% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: INSMED INC, REVOLUTION MEDICINES INC, CYTOKINETICS INC, REGENERON PHARMACEUTICALS, VERA THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 1.4pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-2.3%
Q2 2024
+6.2%
Q3 2024
-7.9%
Q4 2024
-4.7%
Q1 2025
+6.1%
Q2 2025
+26.8%
Q3 2025
+13.7%
Q4 2025
-5.2%
Q1 2026
+19.8%
Sector allocation
Healthcare 90%
Financials 5%
Consumer discretionary 3%
Other 1%
Materials 1%
Long book by quarter
What does Integral Health own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| INSM INSMED INC | Healthcare | 1.5M | $245.3M | 13.0% | +20.0% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 1.5M | $145.9M | 7.7% | +25.0% |
| CYTK CYTOKINETICS INC | Healthcare | 1.6M | $105.5M | 5.6% | +14.3% |
| REGN REGENERON PHARMACEUTICALS | Healthcare | 85.0K | $65.7M | 3.5% | -19.0% |
| VERA VERA THERAPEUTICS INC | Healthcare | 1.6M | $64.4M | 3.4% | -11.1% |
| CAH CARDINAL HEALTH INC | Consumer discretionary | 270.0K | $57.1M | 3.0% | +35.0% |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 2.0M | $55.4M | 2.9% | +135.3% |
| BTSG BRIGHTSPRING HEALTH SERVICES | Healthcare | 1.3M | $53.3M | 2.8% | +66.7% |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 600.0K | $52.2M | 2.8% | +26.3% |
| MRK MERCK & CO. INC. | Healthcare | 425.0K | $51.1M | 2.7% | +70.0% |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 1.6M | $50.4M | 2.7% | +6.7% |
| AZN ASTRAZENECA PLC | Healthcare | 250.0K | $49.3M | 2.6% | New |
| ALHC ALIGNMENT HEALTHCARE INC | Financials | 2.6M | $45.4M | 2.4% | +17.0% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 550.0K | $34.5M | 1.8% | +144.4% |
| LFST LIFESTANCE HEALTH GROUP INC | Healthcare | 4.3M | $27.4M | 1.4% | +43.3% |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 500.0K | $24.6M | 1.3% | +66.7% |
| ELV ELEVANCE HEALTH INC | Financials | 75.0K | $22.0M | 1.2% | +25.0% |
| CNC CENTENE CORP | Financials | 650.0K | $21.3M | 1.1% | Held |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 275.0K | $20.4M | 1.1% | New |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 750.0K | $20.3M | 1.1% | Held |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 150.0K | $19.8M | 1.0% | Held |
| GKOS GLAUKOS CORP | Healthcare | 175.0K | $18.8M | 1.0% | -46.2% |
| ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 300.0K | $18.8M | 1.0% | +200.0% |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 40.0K | $17.9M | 0.9% | New |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.4M | $17.7M | 0.9% | +16.7% |
| ALMS ALUMIS INC | Healthcare | 800.0K | $17.6M | 0.9% | New |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 35.0K | $16.1M | 0.9% | -68.2% |
| QURE UNIQURE NV | Healthcare | 900.0K | $14.7M | 0.8% | Held |
| TARS TARSUS PHARMACEUTICALS INC | Healthcare | 200.0K | $14.0M | 0.7% | Held |
| GILD GILEAD SCIENCES INC | Healthcare | 100.0K | $13.9M | 0.7% | New |
| LLY ELI LILLY & CO | Healthcare | 15.0K | $13.8M | 0.7% | -25.0% |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 170.0K | $13.6M | 0.7% | -47.7% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 350.0K | $13.5M | 0.7% | New |
| ELAN ELANCO ANIMAL HEALTH INC | Healthcare | 550.0K | $13.2M | 0.7% | +120.0% |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 25.0K | $13.1M | 0.7% | New |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 40.0K | $12.9M | 0.7% | Held |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 150.0K | $12.6M | 0.7% | -45.5% |
| RGNX REGENXBIO INC | Healthcare | 1.5M | $12.6M | 0.7% | +25.0% |
| DGX QUEST DIAGNOSTICS INC | Healthcare | 60.0K | $11.8M | 0.6% | -20.0% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 200.0K | $11.6M | 0.6% | New |
| ERAS ERASCA INC | Healthcare | 700.0K | $11.3M | 0.6% | New |
| ANRO ALTO NEUROSCIENCE INC | Healthcare | 500.0K | $11.2M | 0.6% | +33.3% |
| BIIB BIOGEN INC | Healthcare | 60.0K | $11.0M | 0.6% | -40.0% |
| DXCM DEXCOM INC | Healthcare | 175.0K | $11.0M | 0.6% | -65.0% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 325.0K | $10.9M | 0.6% | Held |
| IRON DISC MEDICINE INC | Healthcare | 170.0K | $10.9M | 0.6% | New |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 700.0K | $10.8M | 0.6% | +133.3% |
| CVS CVS HEALTH CORP | Healthcare | 150.0K | $10.8M | 0.6% | -70.0% |
| COO COOPER COS INC/THE | Healthcare | 150.0K | $10.7M | 0.6% | -53.8% |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 20.0K | $9.8M | 0.5% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 90 | $2.09B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 86 | $2.01B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 76 | $1.48B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 72 | $1.09B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 81 | $939.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 83 | $1.17B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 66 | $888.7M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 72 | $1.05B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 80 | $1.08B | canonical | SEC ↗ |